Paul L. Canner

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

Robert Altman, L Carreras, Rubén Sierra Díaz et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1994 · 3.3K citations

Medicine, Pharmacology, Pharmacotherapy +10

Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin

Paul L. Canner, Kenneth G. Berge, Nanette K. Wenger et al. · Journal of the American College of Cardiology · 1986 · 1.8K citations

Medicine, Cardiology, Pharmacology +12

The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial.

Florence H. Sheehan, Eugene Braunwald, Paul L. Canner et al. · Circulation · 1987 · 401 citations · Full text

Medicine, Cardiology, Internal Medicine +12

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)

Paul L. Canner, Curt D. Furberg, Michael L. Terrin et al. · The American Journal of Cardiology · 2005 · 226 citations

Medicine, Cardiology, Pharmacology +16

The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project.

Robert C. Schlant, Sandra Forman, Jeremiah Stamler et al. · Circulation · 1982 · 179 citations

Medicine, Cardiology, Internal Medicine +11